Global Ophthalmics Partnering 2010-2017: Deal Trends, Players and Financials Analysis Report - Research and Markets

DUBLIN--()--The "Global Ophthalmics Partnering 2010-2017: Deal trends, players and financials" report has been added to Research and Markets' offering.

Global Ophthalmics Partnering 2010 to 2017 provides the full collection of Ophthalmics disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

The report includes deals for the following indications: Age-related macular degeneration, Blindness, Cataracts, Conjunctivitis, Diabetic macular edema, Dry eye, Glaucoma, Ocular hypertension, Retinal detachment Retinopathy, Diabetic retinopathy, Uveitis, plus other ophthalmic indications.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Ophthalmics deals.

The report presents financial deal terms values for Ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Global Ophthalmics Partnering 2010 to 2017 includes:

  • Trends in Ophthalmics dealmaking in the biopharma industry since 2010
  • Analysis of Ophthalmics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Ophthalmics deal contract documents
  • Comprehensive access to over 3500 Ophthalmics deal records
  • The leading Ophthalmics deals by value since 2010
  • Most active Ophthalmics dealmakers since 2010

In Global Ophthalmics Partnering 2010 to 2017, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Ophthalmics dealmaking

Chapter 3 -Financial deal terms for Ophthalmics partnering

Chapter 4 - Leading Ophthalmics deals and dealmakers

Chapter 5 - Ophthalmics contract document directory

Chapter 6 - Ophthalmics dealmaking by therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/vzzwgs/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical , Optical Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Optical , Optical Disorders Drugs